Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Stopped early · Early Phase 1 · Has a placebo group

Conditions studied: Subarachnoid Hemorrhage

In brief

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Key facts

Study ID

NCT02216513

Run by

Brigham and Women's Hospital

People needed

2

Starts

2014-09-01

Expected to finish

2015-07-01

Last updated by the study team

2015-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of spontaneous SAH
• impaired cerebral autoregulation on day 2-4 post SAH

You may not qualify if…

• traumatic SAH
• other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
• pregnancy
• severe renal disease or anuria

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.